VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IQV
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IQVIQVIA Holdings Inc.
$257.60$42.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. IQV
  4. Financial Ratios

IQVIA Holdings Inc. (IQV) Financial Ratios

Latest Ratios: P/E Ratio 30.9x · EV/EBITDA 16.0x · ROE 21.4%. (2011–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

IQV Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$42.4B$39.1B$36.0B$43.1B$39.1B$55.0B$34.9B$30.8B$24.2B$21.8B$11.6B
Enterprise Value$56.6B$53.3B$48.5B$55.6B$50.8B$66.1B$46.0B$42.0B$34.3B$31.1B$17.6B
P/E Ratio →30.8628.7526.2431.7435.8257.00125.29160.9593.6916.65100.07
P/S Ratio2.452.402.342.882.713.973.082.782.322.251.70
P/B Ratio6.745.905.947.056.779.115.564.923.482.611.30
P/FCF20.3919.0717.0528.7424.6223.9026.0236.9330.4236.2616.61
P/OCF15.9814.7413.2720.0617.2818.7017.8321.7619.2922.4713.44

P/E links to full P/E history page with 30-year chart

IQV EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—3.273.153.713.534.764.053.793.293.202.58
EV / EBITDA15.9818.8914.6217.9317.3624.8722.8121.2518.2317.9518.86
EV / EBIT25.9423.2020.7326.1028.5843.9758.3452.6246.2348.5331.36
EV / FCF—25.9922.9437.0832.0628.7134.2750.3543.1551.6825.23

IQV Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin33.3%33.3%34.9%35.0%34.9%33.5%34.0%34.2%35.2%35.1%30.3%
Operating Margin13.4%13.4%14.3%13.2%12.5%10.0%6.4%7.0%7.1%7.4%9.4%
Net Profit Margin8.3%8.3%8.9%9.1%7.6%7.0%2.5%1.7%2.5%13.5%1.7%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE21.4%21.4%22.5%22.9%18.5%15.7%4.4%2.9%3.4%15.2%2.6%
ROA4.8%4.8%5.1%5.2%4.4%3.9%1.2%0.8%1.1%6.0%0.9%
ROIC8.3%8.3%8.9%8.2%7.8%6.1%3.1%3.4%3.2%3.3%5.9%
ROCE10.5%10.5%11.0%9.9%9.2%7.1%3.7%4.1%3.8%3.8%6.2%

IQV Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity2.442.442.332.272.262.062.051.921.581.220.81
Debt / EBITDA5.735.734.274.484.444.686.396.085.855.917.73
Net Debt / Equity—2.142.052.052.051.831.771.791.451.110.68
Net Debt / EBITDA5.035.033.764.044.034.175.505.665.385.366.45
Debt / FCF—6.925.898.357.444.818.2613.4212.7215.428.62
Interest Coverage3.153.153.493.174.284.011.901.791.791.853.89

IQV Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio0.750.750.840.860.890.911.121.051.101.221.23
Quick Ratio0.750.750.840.860.890.911.121.051.101.221.23
Cash Ratio0.260.260.260.230.230.280.420.230.270.350.46
Asset Turnover—0.540.570.560.570.560.460.480.460.430.32
Inventory Turnover———————————
Days Sales Outstanding—76.6976.7783.1474.9868.6479.2486.8486.3480.6693.25

IQV Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield3.2%3.5%3.8%3.2%2.8%1.8%0.8%0.6%1.1%6.0%1.0%
FCF Yield4.9%5.2%5.9%3.5%4.1%4.2%3.8%2.7%3.3%2.8%6.0%
Buyback Yield2.9%3.2%3.7%2.3%3.0%0.7%1.3%3.1%5.8%12.0%9.5%
Total Shareholder Yield2.9%3.2%3.7%2.3%3.0%0.7%1.3%3.1%5.8%12.0%9.5%
Shares Outstanding—$174M$183M$186M$191M$195M$195M$200M$208M$223M$152M

Key Metrics

Growth RegimeAccelerating
ProfitabilityModerate
Balance SheetStrained
Cash FlowRobust
Top Statement Risk

Unverified debt swing distorts leverage

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Growth-Adjusted Valuation Looks Undemanding

At 20.98x forward earnings and a 0.85 PEG against mid-single-digit revenue growth, IQVIA appears priced below its own trailing P/E of 34.64; as compiled from current market data, the 14.76x forward EV/EBITDA still sits above ICON's 12.12x but well under Medpace's 32.96x.

The 0.85 PEG suggests the market is paying less than one times growth for a business whose revenue growth reaccelerated to 8.0% in Q3 2026, which appears modest relative to Medpace's 44.1x P/E and 154.9% ROIC. However, the large trailing-to-forward P/E gap implies consensus expects non-cash charges to abate, an assumption that depends on acquisition amortization running off rather than new M&A. The premium to ICON on EV/EBITDA appears to reflect the TAS data franchise, though its durability likely hinges on RDS backlog conversion.

Margin Compression Under Labor Costs

Gross margin has drifted from 35.4% in Q3 2024 to 33.8% in Q3 2026 while operating margin slipped to 12.9%; according to IQVIA's reported quarterly figures, the 160-basis-point gross margin erosion alongside stable operating expense ratios suggests cost inflation in clinical research personnel rather than discretionary overhead.

Gross margin erosion of roughly 160 basis points since Q3 2024 has not been offset at the operating line, where margins have settled near 12-13% versus 14-15% two years ago, implying labor cost growth may be outpacing pricing. Net margin of 7.9% against a 15.1% FCF margin in Q3 2026 indicates reported earnings understate cash generation, largely because of non-cash amortization rather than accrual quality. The Q4 2025 anomaly, where a 6.7% gross margin coexisted with a 16.8% operating margin, suggests one-time items distort period-to-period comparison and warrants reconciliation review.

Returns on Capital Remain Sub-Scale

ROIC has oscillated between 1.8% and 3.2% over ten quarters while ROE reached 8.0% at year-end 2025; based on IQVIA's reported ratios, the gap between the two indicates balance-sheet leverage rather than operating efficiency is doing most of the return work.

ROIC of 3.2% in Q3 2026, while an improvement over the 1.8% recorded in Q2 2026, still appears well below any plausible cost of capital, suggesting the $16.9B goodwill base may not yet be earning an adequate return. The roughly 210-basis-point ROE-to-ROIC spread in the latest quarter implies financial leverage, not asset productivity, is the primary return driver, a dynamic that could reverse quickly if EBITDA softens. Asset turnover of 0.14-0.15x has been essentially flat for ten quarters, pointing to an asset base growing in step with revenue rather than to efficiency gains.

Receivables Stable, Payables Erratic

Days sales outstanding has held in a narrow 71-81 day band across ten quarters while days payable swung from 74 to 123; as disclosed in IQVIA's quarterly filings, that volatility, not collection discipline, appears to be driving working-capital cash swings.

DSO stability suggests contract billing and backlog-to-cash conversion are reasonably well controlled, which is consistent with operating cash flow running above 1.6x net income in every reported period. The DPO swings are large enough to plausibly explain much of the plus-or-minus $100 million quarterly working-capital volatility, and may reflect payment timing rather than durable supplier leverage. Asset turnover near 0.15x is structurally low even for a capital-light services model, which is why inventory-driven metrics such as DIO and the cash conversion cycle remain unavailable and offer limited analytical value here.

Leverage Read Clouded by Debt Anomaly

IQVIA's reported debt-to-equity collapsed from 2.58x in Q2 2026 to 0.22x in Q3 2026, a single-quarter swing that contradicts nine prior periods above 2.0x; based on IQVIA's quarterly ratio disclosures, net debt near 4.9x EBITDA and interest coverage of 3.11x appear the more reliable anchors.

The Q3 2026 print showing D/E of 0.22 and Debt/EBITDA of 1.67 stands in stark contrast to the 2.4-2.7x D/E and 15-20x Debt/EBITDA recorded in the nine preceding quarters, an inconsistency investors should verify against the 10-Q before revising any credit view. Read against the more persistent trailing figures, interest coverage of 3.11x suggests debt service remains manageable but appears to leave limited headroom should Emerging BioPharma clients slow trial starts. If the deleveraging proves real, it would represent a meaningful positive re-rating input; if it proves a reporting artifact, the risk profile is essentially unchanged.

P/E Misreads Amortization-Heavy Earnings

The trailing P/E of 34.64x is the ratio most often misapplied to IQVIA, because roughly $280 million of quarterly non-c cash D&A from prior acquisitions depresses GAAP net margin to 8.34%; per IQVIA's reported reconciliations, adjusted earnings portray a materially different cost of ownership.

D&A of roughly $280 million per quarter runs more than double typical capex, so the earnings denominator carries a non-cash burden that an asset-light services profile would not ordinarily sustain, making the headline multiple look richer than the underlying economics. Investors should instead anchor on EV/EBITDA of 17.16x and P/FCF of 21.79x, while recognizing that FCF margins are themselves distorted by working-capital swings of plus or minus $100 million per quarter. Applying P/E to IQV also obscures segment mix, since recurring TAS revenue would appear to warrant a different multiple than project-based RDS backlog tied to multi-year conversion timing.

Download Financial Ratios Data

Includes 30+ ratios · 15 years · Updated daily

Consensus & Technical Research Suite
Open IQV Terminal

IQV Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

IQV — Frequently Asked Questions

Quick answers to the most common questions about buying IQV stock.

What is IQVIA Holdings Inc.'s P/E ratio?

IQVIA Holdings Inc.'s current P/E ratio is 30.9x. The historical average is 57.4x. This places it at the 46th percentile of its historical range.

What is IQVIA Holdings Inc.'s EV/EBITDA?

IQVIA Holdings Inc.'s current EV/EBITDA is 16.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.8x.

What is IQVIA Holdings Inc.'s ROE?

IQVIA Holdings Inc.'s return on equity (ROE) is 21.4%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 13.0%.

Is IQV stock overvalued?

Based on historical data, IQVIA Holdings Inc. is trading at a P/E of 30.9x. This is at the 46th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are IQVIA Holdings Inc.'s profit margins?

IQVIA Holdings Inc. has 33.3% gross margin and 13.4% operating margin. Operating margin between 10-20% is typical for established companies.

How much debt does IQVIA Holdings Inc. have?

IQVIA Holdings Inc.'s Debt/EBITDA ratio is 5.7x, indicating high leverage. A ratio above 4x may signal elevated financial risk.